Literature DB >> 2540344

Studies on the mechanisms of granulocyte dysfunctions in severely burned patients--evidence for altered leukotriene generation.

M Köller1, W König, J Brom, G Erbs, F E Müller.   

Abstract

The leukotriene generation (LTB4, 20-OH-LTB4, 20-COOH-LTB4) from PMNs of severely burned patients (n = 6) was studied by reversed-phase HPLC. Granulocytes from all patients showed a decrease in leukotriene generation which only returned to normal levels when the patients recovered from their injuries. The leukotriene generation induced by different stimuli, i.e., the Ca++-ionophore A23187 (7.3 microM) or opsonized zymosan (2 mg) in the presence of exogenous arachidonic acid (60 microM) showed similar stimulation profiles. The cellular differentiation of the respective granulocyte fractions revealed that the decreased leukotriene generation was accompanied by the occurrence of immature granulocytes in the peripheral blood. Furthermore, the studies in the presence of exogenous arachidonic acid showed that the defect in leukotriene generation from granulocytes of surviving patients was due to the availability of metabolizable substrate (i.e., free arachidonic acid). Granulocytes from one nonsurviving patient showed in addition a defect in the metabolic ability of arachidonic acid to generate the respective leukotrienes. The generation of reactive oxygen species did not correlate with the observed alterations in the formation of the leukotrienes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540344     DOI: 10.1097/00005373-198904000-00004

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  10 in total

Review 1.  Microbial pathogenicity and host defense in burned patients--the role of inflammatory mediators.

Authors:  W König; B Schlüter; J Scheffer; M Köller
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 2.  The immunologic response to thermal injury.

Authors:  M Heideman; A Bengtsson
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

3.  Arachidonic acid metabolism in heat-shock treated human leucocytes.

Authors:  M Köller; W König
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

4.  Decreased leukotriene release from neutrophils after severe trauma: role of immature cells.

Authors:  M Köller; M Wick; G Muhr
Journal:  Inflammation       Date:  2001-02       Impact factor: 4.092

5.  Induction of inflammatory mediator release (serotonin and 12-hydroxyeicosatetraenoic acid) from human platelets by Pseudomonas aeruginosa glycolipid.

Authors:  B König; U Bergmann; W König
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

6.  Serum CD14 levels in polytraumatized and severely burned patients.

Authors:  C Krüger; C Schütt; U Obertacke; T Joka; F E Müller; J Knöller; M Köller; W König; W Schönfeld
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

7.  GTP-binding proteins are involved in the modulated activity of human neutrophils treated with the Panton-Valentine leukocidin from Staphylococcus aureus.

Authors:  T Hensler; M Köller; G Prévost; Y Piémont; W König
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  U75412E, a lazaroid, prevents progressive burn ischemia in a rat burn model.

Authors:  M Choi; H P Ehrlich
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

9.  Staphylococcus aureus toxic shock syndrome toxin 1 and Streptococcus pyogenes erythrogenic toxin A modulate inflammatory mediator release from human neutrophils.

Authors:  T Hensler; M Köller; C Geoffroy; J E Alouf; W König
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

10.  Leukotriene B4 generation and DNA fragmentation induced by leukocidin from Staphylococcus aureus: protective role of granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF for human neutrophils.

Authors:  T Hensler; B König; G Prévost; Y Piémont; M Köller; W König
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.